Polymethoxylated flavones induce Ca(2+)-mediated apoptosis in breast cancer cells

Igor N Sergeev1, Shiming Li, Julie Colby

  • 1Department of Nutrition, Food Science and Hospitality, South Dakota State University, Brookings, SD 57007, USA. igor.sergeev@sdstate.edu

Life Sciences
|October 19, 2006
PubMed

Insights

Polymethoxyflavones (PMFs) from sweet oranges induce breast cancer cell death by increasing intracellular calcium (Ca2+). Hydroxylated PMFs are more effective, activating Ca2+-dependent proteases for apoptosis.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Cancer Research

Background:

  • Flavonoids are dietary polyphenols with suggested anticancer properties.
  • The apoptotic mechanisms of flavonoids remain largely unknown.
  • Previous research indicated isoflavones activate a Ca(2+)-mediated apoptotic pathway.

Purpose of the Study:

  • To investigate the anticancer effects of polymethoxyflavones (PMFs) from sweet oranges on human breast cancer cells.
  • To elucidate the role of intracellular calcium (Ca2+) in PMF-induced apoptosis.
  • To determine the structural requirements for PMF-induced apoptosis.

Main Methods:

  • Treatment of MCF-7 breast cancer cells with specific hydroxylated and non-hydroxylated PMFs.
  • Measurement of intracellular Ca2+ ([Ca2+]i) concentrations.
  • Assay of Ca(2+)-dependent apoptotic proteases (mu-calpain and caspase-12) activity.
  • Evaluation of endoplasmic reticulum Ca2+ stores and extracellular Ca2+ influx.

Main Results:

  • Hydroxylated PMFs (5-OH-HxMF, 3'-OH-TtMF) significantly increased [Ca2+]i in MCF-7 cells.
  • This Ca2+ increase resulted from ER Ca2+ depletion and extracellular influx.
  • Increased [Ca2+]i correlated with activation of mu-calpain and caspase-12.
  • Non-hydroxylated PMFs showed significantly less apoptotic activity.
  • Hydroxylation of PMFs is critical for their Ca(2+)-dependent apoptotic effects.

Conclusions:

  • PMFs from sweet oranges inhibit human breast cancer cell growth via a Ca(2+)-dependent apoptotic mechanism.
  • The ability of PMFs to modulate intracellular Ca2+ is central to their apoptotic activity.
  • Hydroxylation is a key structural feature enabling PMFs to induce Ca(2+)-mediated apoptosis.

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...